5 days ago
HomeMarket NewsStocks NewsZydus Lifesciences’ Maharashtra unit clears US FDA inspection with no observations
Zydus Lifesciences' US formulation sales for the third quarter stood at $285 million, which is a growth of 29% on a year-on-year basis. Shares of Zydus Lifesciences Ltd ended at ₹901.60, down by ₹40.85, or 4.33%, on the BSE.
Zydus Lifesciences Ltd on Friday (February 14) announced the successful completion of a US Food and Drug Administration (FDA) surveillance inspection at its API (active pharmaceutical ingredient) manufacturing facility in Ambernath, Maharashtra.
The inspection, conducted from February 10 to 14, 2025, concluded with no observations.
"We wish to inform that the USFDA conducted a surveillance inspection at the group’s API Manufacturing site situated at Ambernath in Maharashtra. The inspection was conducted from February 10th to 14th, 2025. The inspection concluded with NIL observations," Zydus Lifesciences said in a regulatory filing.
Also Read: USFDA clears Zydus Lifesciences’ Ahmedabad facility with zero observation
Zydus Lifesciences' US formulation sales for the third quarter stood at $285 million, which is a growth of 29% on a year-on-year (YoY) basis. The figure is also higher than the $270-million estimate. The US contributes nearly 47% to Zydus Life's overall topline.
Revenue during the quarter grew by 17% for the company to ₹5,269 crore, while its net profit stood at ₹1,023 crore from ₹789 crore last year, implying a growth of 30%. The company's profitability was aided by a surge in its forex gain, which stood at ₹183 crore during the quarter, compared to a gain of ₹21 crore during the same quarter last year.
Zydus Life's earnings before interest, tax, depreciation and amortisation (EBITDA) stood at ₹1,387 crore at the end of the December quarter. The company had reported an EBITDA of ₹1,102 crore in the base quarter. EBITDA margin expanded by nearly 200 basis points to 26.3% from 24.5% last year.
Also Read: Zydus Lifesciences secures exclusive US rights for BEIZRAY in licensing deal with Beihai Biotech
The company's net-debt-to-equity ratio as of December 13 stood at a negative 0.14 times, compared to a negative 0.47 times at the end of the December quarter last year.
Shares of Zydus Lifesciences Ltd ended at ₹901.60, down by ₹40.85, or 4.33%, on the BSE.
(Edited by : Shoma Bhattacharjee)
